XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Schedule of Revenues from Major Customers (Detail) - Product Concentration Risk [Member] - Revenue Benchmark [Member]
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Largest Customer | HEPLISAV-B        
Concentration Risk [Line Items]        
Percentage of product revenue 23.00% 22.00% 20.00% 21.00%
Second Largest Customer | HEPLISAV-B        
Concentration Risk [Line Items]        
Percentage of product revenue 19.00% 20.00% 18.00% 21.00%
Third Largest Customer | HEPLISAV-B        
Concentration Risk [Line Items]        
Percentage of product revenue 18.00% 19.00% 17.00% 18.00%
Largest Collaboration Partner | CpG 1018 adjuvant        
Concentration Risk [Line Items]        
Percentage of product revenue 69.00% 62.00% 46.00% 45.00%
Second Largest Collaboration Partner | CpG 1018 adjuvant        
Concentration Risk [Line Items]        
Percentage of product revenue 22.00% 30.00% 33.00% 29.00%
Third largest collaboration partner | CpG 1018 adjuvant        
Concentration Risk [Line Items]        
Percentage of product revenue 9.00% 8.00% 15.00% 13.00%